首页> 外文期刊>BMC Palliative Care >Is shared decision-making vanishing at the end-of-life? A descriptive and qualitative study of advanced cancer patients’ involvement in specific therapies decision-making
【24h】

Is shared decision-making vanishing at the end-of-life? A descriptive and qualitative study of advanced cancer patients’ involvement in specific therapies decision-making

机译:共同的决策在生命的尽头消失了吗?对晚期癌症患者参与特定疗法决策的描述性和定性研究

获取原文
           

摘要

Little is known about what is at stake at a subjective level for the oncologists and the advanced cancer patients when they face the question whether to continue, limit or stop specific therapies. We studied (1) the frequency of such questioning, and (2) subjective determinants of the decision-making process from the physicians’ and the patients’ perspectives. (1) All hospitalized patients were screened during 1?week in oncology and/or hematology units of five institutions. We included those with advanced cancer for whom a questioning about the pursuit, the limitation or the withholding of specific therapies (QST) was raised. (2) Qualitative design was based on in-depth interviews. In conventional units, 12.8?% of cancer patients (26 out of 202) were concerned by a QST during the study period. Interviews were conducted with all physicians and 21 advanced cancer patients. The timing of this questioning occurred most frequently as physicians estimated life expectancy between 15?days and 3?months. Faced with the most frequent dilemma (uncertain risk-benefit balance), physicians showed different ways of involving patients. The first two were called the “no choice” models: 1) trying to resolve the dilemma via a technical answer or a “wait-and-see” posture, instead of involving the patients in the questioning and the thinking; and 2), giving a “last minute” choice to the patients, leaving to them the responsibility of the decision. In a third model, they engaged early in shared reflections and dialogue about uncertainties and limits with patients, proxies and care teams. These schematic trends influenced patients’ attitudes towards uncertainty and limits, as they were influenced by these ones. Individual and systemic barriers to a shared questioning were pointed out by physicians and patients. This study indicate to what extent these difficult decisions are related to physicians’ and patients’ respective and mutually influenced abilities to deal with and share about uncertainties and limits, throughout the disease trajectory. These insights may help physicians, patients and policy makers to enrich their understanding of underestimated and sensitive key issues of the decision-making process.
机译:当肿瘤学家和癌症晚期患者面临继续,限制或停止特定治疗​​的问题时,对主观水平上的风险知之甚少。我们研究了(1)这种询问的频率,以及(2)从医生和患者的角度对决策过程的主观决定因素。 (1)在5个机构的肿瘤学和/或血液学部门对所有住院患者进行了1周的筛查。我们纳入了那些患有晚期癌症的患者,这些患者提出了对特定疗法的追求,局限性或保留权的质疑。 (2)定性设计基于深入的访谈。在常规期间,在研究期间,有12.8%的癌症患者(202名患者中的26名)与QST有关。对所有医生和21位晚期癌症患者进行了访谈。由于医生估计预期寿命在15天至3个月之间,因此这种询问的时间最频繁。面对最常见的困境(不确定的风险收益平衡),医生展示了让患者参与的不同方式。前两个被称为“无选择”模型:1)试图通过技术回答或“观望”姿态解决困境,而不是让患者参与质疑和思考。 2)给患者“最后一刻”的选择权,让他们承担决定的责任。在第三个模型中,他们尽早与患者,代理和护理团队就不确定性和限制进行了共同的思考和对话。这些示意性趋势影响了患者对不确定性和极限的态度,因为它们受到这些趋势的影响。医师和患者指出了共同提问的个人和系统障碍。这项研究表明,这些困难的决定在多大程度上与医师和患者在整个疾病轨迹上应对和分享不确定性和界限的能力有关,并且相互影响。这些见解可以帮助医生,患者和决策者加深对决策过程中被低估和敏感的关键问题的理解。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号